CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines The Prevalence of Myocardial Bridging Associated with Coronary Endothelial Dysfunction in Patients with Chest Pain and Non-Obstructive Coronary Artery Disease Myocardial bridging: contemporary understanding of pathophysiology with implications for diagnostic and therapeutic strategies Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes When, where, and how to target vascular inflammation in the post-CANTOS era? Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT

Clinical Trial2021 Feb 16;143(7):673-684.

JOURNAL:Circulation. Article Link

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

TA Zelniker, M Ardissino, F Andreotti et al. Keywords: AF; AMI with atrial fibrillation and CHADS2 score ≥2; higher-dose edoxaban vs.lower-dose edoxaban regimen; warfarin; gender difference

Full Text PDF